Tirzepatide · 22 May 2026
Tirzepatide: The Dual GIP/GLP-1 Agonist in Incretin Research
Essential Peptides Au · Journal · 4 min read
A dual GIP/GLP-1 receptor agonist, and a more recent entrant than Semaglutide. Studied in similar metabolic contexts but with the added GIP receptor activity producing a distinct pharmacological profile in the literature. Comparative studies between Tirzepatide and single-agonist GLP-1 compounds are an active area of current research.
Mechanism in brief
Tirzepatide engages both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R, each coupling through Gs to stimulate cAMP production. Its GIPR agonism shows a differentiated β-arrestin recruitment profile relative to native GIP in cellular assays — sometimes described as partial or biased agonism — which creates distinct receptor internalisation kinetics compared with full-efficacy GIPR agonists.
At GLP-1R it behaves as a full agonist with potency comparable to semaglutide in cAMP accumulation assays. A C20 fatty diacid modification confers tight albumin binding, supporting comparative half-life studies against C18-modified analogs.
In current research
Dual-receptor research panels typically aim to dissect how simultaneous GIP and GLP-1 pathway activation changes the net cAMP response, receptor trafficking, or downstream transcriptional outputs versus each pathway individually. Its biased GIPR profile makes it an informative tool for structure-activity work.
Cross-panel comparisons with single-pathway GLP-1R agonists and the triple-agonist retatrutide are a common way to map receptor-selectivity contributions across the incretin class.
View compound
Tirzepatide in the catalogue
Related reading
For research use only. This article is provided for research and educational purposes and does not describe or imply therapeutic use. None of these compounds are for human or veterinary consumption.